page_title: Migalastat
section_title: Chemistry
hierarchical_section_title: Migalastat / Chemistry
context_page_description: Migalastat is a drug for the treatment of Fabry disease, a rare genetic disorder. It was developed by Amicus Therapeutics. The US Food and Drug Administration assigned it orphan drug status in 2004, and the European Committee for Orphan Medicinal Products followed in 2006. The European Medicines Agency's Committee for Medicinal Products for Human Use granted the drug a marketing approval under the name Galafold in May 2016.
context_section_description: Migalastat is used in form of the hydrochloride, which is a white crystalline solid and is soluble in water. The molecule has four asymmetric carbon atoms with the same stereochemistry as the sugar D-galactose, but is missing the first hydroxyl group. It has a nitrogen atom in the ring instead of an oxygen, which makes it an iminosugar.
  The structure is formally derived from nojirimycin.
caption: D-Galactose, for comparison